Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA
- Written by ACN Newswire
|
"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."
Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.
Topic: Press release summarySectors: Daily Finance, Daily News, BioTech[1][2][3] http://www.acnnewswire.com From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
References
- ^ Daily Finance (www.acnnewswire.com)
- ^ Daily News (www.acnnewswire.com)
- ^ BioTech (www.acnnewswire.com)
Read more http://www.acnnewswire.com/press-release/english/45184/